Fosamprenavir Expanded Access

ViiV Healthcare

Status and phase: Completed; Phase 4

Conditions: Infection, Human Immunodeficiency Virus

Treatments: Drug: Telzir®; Drug: fosamprenavir

Study type: Interventional

Funder types: Industry

Identifiers

NCT00240552

APV40005

Details and patient eligibility

About

This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.

Enrollment: 85 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• HIV-1 infected subjects.

• Subjects must belong to one of the following populations:

  1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
  2. Subjects who already receive amprenavir (Agenerase®)
  3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.